A mechanistically novel peptide agonist of the IL-7 receptor that addresses limitations of IL-7 cytokine therapy.
Interleukin (IL)-7 is broadly active on T-cell populations, and modified versions have been clinically evaluated for a variety of therapeutic applications, including cancer, lymphopenia, and infectious diseases; and found to be relatively well-tolerated and biologically active. Here we describe nove...
Furkejuvvon:
| Váldodahkkit: | , , , , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Public Library of Science (PLoS)
2023-01-01
|
| Ráidu: | PLoS ONE |
| Liŋkkat: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0286834&type=printable |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|